Literature DB >> 23225407

[Epidemiology, diagnosis and treatment of adult patients with nosocomial pneumonia. S-3 Guideline of the German Society for Anaesthesiology and Intensive Care Medicine, the German Society for Infectious Diseases, the German Society for Hygiene and Microbiology, the German Respiratory Society and the Paul-Ehrlich-Society for Chemotherapy].

K Dalhoff1, M Abele-Horn, S Andreas, T Bauer, H von Baum, M Deja, S Ewig, P Gastmeier, S Gatermann, H Gerlach, B Grabein, G Höffken, W V Kern, E Kramme, C Lange, J Lorenz, K Mayer, I Nachtigall, M Pletz, G Rohde, S Rosseau, B Schaaf, R Schaumann, D Schreiter, H Schütte, H Seifert, H Sitter, C Spies, T Welte.   

Abstract

Nosocomial pneumonia (HAP) is a frequent complication of hospital care. Most data are available on ventilator-associated pneumonia. However infections on general wards are also increasing. A central issue are infections with multi drug resistant (MDR) pathogens which are difficult to treat particularly in the empirical setting potentially leading to inappropriate use of antimicrobial therapy. This guideline was compiled by an interdisciplinary group on the basis of a systematic literature review. Recommendations are made according to GRADE giving guidance for the diagnosis and therapy of HAP on the basis of quality of evidence and benefit/risk ratio. The guideline has two parts. First an update on epidemiology, spectrum of pathogens and antiinfectives is provided. In the second part recommendations for the management of diagnosis and treatment are given. Proper microbiologic work up is emphasized for knowledge of the local patterns of microbiology and drug susceptibility. Moreover this is the optimal basis for deescalation in the individual patient. The intensity of antimicrobial therapy is guided by the risk of infections with MDR. Structured deescalation concepts and strict limitation of treatment duration should lead to reduced selection pressure. © Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23225407     DOI: 10.1055/s-0032-1325924

Source DB:  PubMed          Journal:  Pneumologie        ISSN: 0934-8387


  31 in total

1.  [Treatment of invasive mycoses. What can be done when therapy fails?].

Authors:  F Bloos
Journal:  Anaesthesist       Date:  2015-09       Impact factor: 1.041

Review 2.  [Antibiotic stewardship : Measures for optimizing prescription of anti-infective agents].

Authors:  C Lanckohr; H Bracht
Journal:  Anaesthesist       Date:  2018-01       Impact factor: 1.041

3.  [Ventilator-associated pneumonia].

Authors:  S Rosseau; H Schütte; N Suttorp
Journal:  Internist (Berl)       Date:  2013-08       Impact factor: 0.743

4.  [Infections due to multidrug-resistant pathogens : Pathogens, resistance mechanisms and established treatment options].

Authors:  D C Richter; T Brenner; A Brinkmann; B Grabein; M Hochreiter; A Heininger; D Störzinger; J Briegel; M Pletz; M A Weigand; C Lichtenstern
Journal:  Anaesthesist       Date:  2019-10       Impact factor: 1.041

Review 5.  [Severe pneumonia in the intensive care unit].

Authors:  T Welte
Journal:  Med Klin Intensivmed Notfmed       Date:  2016-05-09       Impact factor: 0.840

Review 6.  [Nosocomial pneumonia from a radiological perspective].

Authors:  P Agarwal; A Wielandner
Journal:  Radiologe       Date:  2017-01       Impact factor: 0.635

7.  In reply.

Authors:  Klaus Dalhoff; Santiago Ewig
Journal:  Dtsch Arztebl Int       Date:  2014-01-06       Impact factor: 5.594

Review 8.  [Rational use of antibiotics].

Authors:  P Walger
Journal:  Internist (Berl)       Date:  2016-06       Impact factor: 0.743

Review 9.  [Criteria for treating MRSA in sputum].

Authors:  J Lorenz; M Unnewehr; B Schaaf; S Gatermann
Journal:  Internist (Berl)       Date:  2017-11       Impact factor: 0.743

10.  I-FABP is a Novel Marker for the Detection of Intestinal Injury in Severely Injured Trauma Patients.

Authors:  M Voth; M Duchene; B Auner; T Lustenberger; B Relja; I Marzi
Journal:  World J Surg       Date:  2017-12       Impact factor: 3.352

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.